March 17, 1999 17:36
Endovasc Expands Phase I/II Clinical Trials to Renowned French
Research Institute; Agreements with Polyclinique d'Essey-les-Nancy
MONTGOMERY, Texas--(BUSINESS WIRE)--March 17, 1999--Endovasc Ltd. Inc. (OTC BB:ENDV) today
announced an expansion of its Critical Limb Ischemia (CLI) therapy program to include doctors and
scientists at Polyclinique of Nancy, France. The agreement involves testing the therapeutic effects of its
new product, Liprostin(TM), in salvaging limbs that would otherwise be amputated due to peripheral
occlusive vascular disease (POVD). POVD is a progressive disease that blocks blood circulation to the
extremities, eventually resulting in amputation.
Endovasc Ltd. Inc. will provide Liprostin(TM) adjunctive drug treatment to mechanical intervention with
balloon catheter dilation and stent placement to open and maintain blood flow, thus saving the limb. Dr.
Michel Henry, FACA, FACC, a prominent French cardiologist, will conduct the clinical trials in France.
"Now that we have funding for these trials, we can accelerate the completion of the Phase I/II trials along
the lines suggested by the FDA in our recent preclinical discussion," stated company spokesman, Dr.
David P. Summers. "This is a large, though virtually untreated disease, that especially afflicts the elderly."
Endovasc Ltd. Inc. is a biopharmaceutical company using liposomal drug delivery for products that have
already shown safety and efficacy in the generic form. The company's products and processes are
covered by patents and trade secrets for competing in a $2 billion market.
The foregoing statements are made under the "Safe Harbor" Private Securities Litigation Reform Act of
1995 and may contain forward-looking statements that involve risks and uncertainties that may not be
evident at the time of this release.
CONTACT: PMR and Associates, Encinitas
760/635-8695
E-mail: pmrandco@aol.com
Claudia |
